However, Cancer Prevention Pharmaceuticals (CPP) has been working on a Phase 3 trial for a potential new therapy for the condition and they’ve just announced that the last of their participants has completed the protocol. The goal of this drug is The hope is that this drug will minimize or eliminate the need for FAP-related events. Data from this trial should be available early in the new year.
The Trial
The trial was designed to evaluate CPP-1X/sul as a treatment for FAP. This drug has already received fast track designation and orphan drug designation by the FDA.
CPP’s trial of the drug began five years ago. It was conducted at 17 sites across the United States, Europe, and Canada. The organization believes that the drug could be life-changing for patients, as they think it could reduce and potentially completely eliminate FAP-related events. This means patients would not need to undergo surgical or endoscopic interventions.
CPP’s trial involved a total of 171 patients, making it the largest ever created for this condition. It was also the longest trial ever conducted for FAP.
Specifically, the trial compared the combination of CPP-1X with sulindac with sulindac and CPP-1X on their own. You can read more about the specifics of the trial here.
If everything stays on schedule, we should hear the results of this trial very shortly. If approved, this drug could significantly improve not only outcomes for FAP patients, but their quality of life.
You can read more updates on CPP and this trial here.
